Huons Re-signs Exclusive Sales Contract for 'Selenaze' with BioSyn Korea

Exclusive Domestic Sales Until 2028

Huons recently announced on the 1st that it has signed a contract renewal with Biosyn Korea at its headquarters in Pangyo, Seongnam, for the exclusive domestic sales of 'Selenase.'

Huons Group signed a contract renewal for the exclusive domestic sales of SelenaZ with Biosyn Korea at their Seongnam Pangyo office on the 29th of last month. Yoon Sang-bae, CEO of Huons (left), and Kim Hyung-ho, Vice President of Biosyn Korea, are posing for a commemorative photo.
[Photo by Huons]

This contract expands and extends the existing exclusive domestic sales agreement for Selenase, which the two companies originally signed in 2013. Huons explained that the renewal was made based on mutual trust and a shared understanding of the high growth potential between the two companies.

Through this contract renewal, Huons has secured the exclusive domestic sales rights for high-dose selenium injections and oral solutions of Selenase until 2028.

Selenase is a pharmaceutical product used to treat diseases caused by selenium deficiency. It was researched, developed, and first launched by Germany’s Biosyn in 1987 and currently records blockbuster sales of around 12 billion KRW annually. In South Korea, it is prescribed in general hospitals, nursing hospitals, and clinics.

Huons plans to actively contribute to improving public health by expanding the domestic supply of Selenase. Selenase has demonstrated antioxidant effects as well as clinical trial results for 40 conditions including cancer, sepsis, autoimmune thyroiditis, hepatitis, and cardiovascular diseases. In June, clinical results of high-dose selenium (sodium selenite) treatment targeting cancer patients were presented at the International Selenium Society conference. In South Korea, it has been imported through Biosyn Korea and exclusively sold by Huons since August 2013.

A Huons representative stated, "We are pleased to have secured the exclusive domestic sales rights for Selenase again," and added, "We will expand the supply of Selenase to contribute to the improvement of public health."

Meanwhile, in South Korea, the prescription drugs 'Selenase 100 Microgram Pro (100 pro) Injection' and 'Selenase T Pro (T pro) Injection,' which contains high-dose selenium of 500-1000㎍ per vial, are distributed. As over-the-counter drugs, the oral products 'Selenase 100 Microgram Peroral Solution (100㎍ peroral)' and 'Selenase T Peroral Solution (500㎍ peroral)' are available.

This content was produced with the assistance of AI translation services.